Skip to content
Search

Latest Stories

Smith & Nephew names Deepak Nath as CEO

Medical devices maker Smith & Nephew has appointed Siemens Healthineers' Deepak Nath as chief executive, replacing Roland Diggelmann after the company narrowly missed analysts' estimate for annual profit.

Diggelmann was brought in after the company's former boss left over pay in late 2019, and the British firm was counting his more than 20 years' experience in the orthopaedics and diagnostics sectors to accelerate its revenue growth.


However, the pandemic hit soon after, forcing hospitals to delay elective surgeries and services to accommodate Covid-19 patients, and hitting demand for the company's hip and knee replacements while supply chain issues also weighed it down.

Smith & Nephew said Diggelmann was leaving “by mutual agreement” on March 31.

Revenue at the British company rose 10.3 per cent to $5.21 billion in the 12 months ended Dec. 31 on an underlying basis, steadily recovering from 2020, while trading profit came in at $936 million, compared with $683 million in the previous year.

Healthcare networks globally are under pressure again by the new Omicron coronavirus variant, and the company is targeting underlying revenue growth in the range 4.0 to 5.0 per cent for 2022.

Nath, who was previously president of diagnostics at Siemens, will start at Smith & Nephew from April 1.

"(Deepak Nath) is joining us at an inflection point for the business and will bring his drive, experience and expertise to lead the team in delivering our Strategy for growth at pace," chairman Roberto Quarta said in a statement.

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less